Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.45 |
| ▸ | MAOB | P27338 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531604 | 0.89 | PIM1 (0.46) | PIM1PIM2SRCDRD1MAOA | |
| SCHEMBL68710 | 0.84 | PIM1 (0.52) | PIM1PIM2SRCDRD1MAOA | |
| SCHEMBL29394922 | 0.84 | PIM1 (0.52) | PIM1PIM2SRCDRD1MAOA | |
| SCHEMBL18001880 | 0.83 | DRD1 (0.71) | PIM1PIM2DRD1MAPTALDH1A1 | |
| SCHEMBL19595301 | 0.83 | PIM1 (0.52) | PIM1PIM2TDP1MAPTHTT | |
| SCHEMBL498326 | 0.81 | PIM1 (0.48) | PIM1PIM2NPC1RAB9AMAPT | |
| SCHEMBL5576877 | 0.81 | SRC (0.49) | PIM1PIM2SRCDRD1MAOA | |
| SCHEMBL856123 | 0.80 | DRD1 (0.68) | SRCDRD1MAOAMAOBNPC1 | |
| SCHEMBL29391855 | 0.80 | DRD1 (0.68) | SRCDRD1MAOAMAOBNPC1 | |
| SCHEMBL27676782 | 0.79 | PIM1 (0.49) | PIM1PIM2SRCMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2744788-B1 | BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9423396-B2 | Bodipy structure fluorescence probes for diverse biological applications | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-08-23 | — | — | US | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9164376-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | GLOBALFOUNDRIES INC. (KY) | 2015-10-20 | — | — | US | disclosed |
| WO-1998010286-A1 | METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998005961-A1 | COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0818431-A1 | Scavenger assisted combinatorial process for preparing libaries of secondary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0816310-A2 | Scavenger assisted combinatorial process for preparing libraries of tertiary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997017950-A1 | SHOULDER PROSTHESIS | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774455-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-4707486-A | Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary therapeutic use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | PIM1 4817/4885PIM2 4827/4885SRC 1248/4885 |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | NR1H3, NR1H2, NR1H4 | PIM1 4817/4885PIM2 4827/4885SRC 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.